Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1954 2
1955 1
1956 2
1958 2
1959 1
1960 1
1961 2
1962 1
1963 1
1964 4
1965 4
1966 4
1968 3
1969 1
1970 2
1971 4
1972 4
1973 5
1974 2
1975 4
1976 1
1978 1
1982 3
1983 2
1984 3
1985 1
1986 2
1987 1
1988 3
1990 3
1991 2
1992 6
1993 3
1994 6
1995 6
1996 1
1997 5
1998 2
1999 5
2000 7
2001 6
2002 5
2003 4
2004 8
2005 4
2006 8
2007 5
2008 4
2009 5
2010 8
2011 6
2012 16
2013 14
2014 11
2015 11
2016 13
2017 12
2018 14
2019 15
2020 14
2021 10
2022 6
2023 10
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Dombi E, et al. Among authors: ratner n. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. N Engl J Med. 2016. PMID: 28029918 Free PMC article. Clinical Trial.
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, Allen JC, Schorry E, Korf B, Robison NJ, Goldman S, Vinks AA, Emoto C, Fukuda T, Robinson CT, Cutter G, Edwards L, Dombi E, Ratner N, Packer R, Fisher MJ. Weiss BD, et al. Among authors: ratner n. J Clin Oncol. 2021 Mar 1;39(7):797-806. doi: 10.1200/JCO.20.02220. Epub 2021 Jan 28. J Clin Oncol. 2021. PMID: 33507822 Free PMC article. Clinical Trial.
Schwann cells modulate nociception in neurofibromatosis 1.
Raut NG, Maile LA, Oswalt LM, Mitxelena I, Adlakha A, Sprague KL, Rupert AR, Bokros L, Hofmann MC, Patritti-Cram J, Rizvi TA, Queme LF, Choi K, Ratner N, Jankowski MP. Raut NG, et al. Among authors: ratner n. JCI Insight. 2024 Jan 23;9(2):e171275. doi: 10.1172/jci.insight.171275. JCI Insight. 2024. PMID: 38258905 Free PMC article.
Purinergic signaling in peripheral nervous system glial cells.
Patritti-Cram J, Coover RA, Jankowski MP, Ratner N. Patritti-Cram J, et al. Among authors: ratner n. Glia. 2021 Aug;69(8):1837-1851. doi: 10.1002/glia.23969. Epub 2021 Jan 28. Glia. 2021. PMID: 33507559 Free PMC article. Review.
Neurofibromatosis type 1: modeling CNS dysfunction.
Gutmann DH, Parada LF, Silva AJ, Ratner N. Gutmann DH, et al. Among authors: ratner n. J Neurosci. 2012 Oct 10;32(41):14087-93. doi: 10.1523/JNEUROSCI.3242-12.2012. J Neurosci. 2012. PMID: 23055477 Free PMC article. Review.
RUNX represses Pmp22 to drive neurofibromagenesis.
Hall A, Choi K, Liu W, Rose J, Zhao C, Yu Y, Na Y, Cai Y, Coover RA, Lin Y, Dombi E, Kim M, Levanon D, Groner Y, Boscolo E, Pan D, Liu PP, Lu QR, Ratner N, Huang G, Wu J. Hall A, et al. Among authors: ratner n. Sci Adv. 2019 Apr 24;5(4):eaau8389. doi: 10.1126/sciadv.aau8389. eCollection 2019 Apr. Sci Adv. 2019. PMID: 31032403 Free PMC article.
309 results